
Regeneron’s Strategic Capital Allocation: A Defensive Approach to Profit Maximization
Regeneron’s Strategic Moves in 2025: Defensive Capital Allocation and Growth Drivers Regeneron Pharmaceuticals Inc. (REGN) kicked off the year 2025 with a strategic shift in capital allocation, aiming to protect its profits and fuel growth. The biopharmaceutical company announced the initiation of a dividend and an expanded share buyback program, signaling its commitment to returning…